SWOG clinical trial number
S1107

Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma

71% Accrual
Accrual
71%
Closed
Phase
71% Accrual
Accrual
71%
Abbreviated Title
Papillary Renal, ARQ 197 +/- Erlotinib, Ph II
Activated
08/20/2012
Closed
05/29/2014
Participants
NCORP, Members, Medical Oncologists, Surgeons, CTSU, Affiliates

Research committees

Genitourinary Cancer

Treatment

Erlotinib ARQ 197

Other Clinical Trials

S2312
SWOG Clinical Trial Number
S2210
SWOG Clinical Trial Number
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
11% Accrual
Accrual
11%
Open
Phase
S2200
SWOG Clinical Trial Number
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
17% Accrual
Accrual
17%
Open
Phase